MedTrace Logo

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

NCT02977689 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-12-20

No results posted yet for this study

Summary

The purpose of this study is to found out if the drug IDH305 is safe and effective in subjects with IDH1 mutant grade II or III glioma that has progressed after observation or radiation therapy.

Conditions

Interventions

DRUG

IDH305

study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.

Sponsors & Collaborators

Principal Investigators

  • Andrew S Chi, MD, PhD · NYU Perlmutter Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-30
Primary Completion
2020-04-30
Completion
2020-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02977689 on ClinicalTrials.gov